Science Flash
clinical study

bone & tissue regeneration

botiss biomaterials

mucoderm® an efficient alternative for peri-implant soft tissue augmentation Part I

Scientific source:
Zafiropoulos GG, Deli G, Hoffmann O, John G. Changes of the peri-implant soft tissue thickness after grafting with a collagen matrix. J Indian Soc Periodontol 2016; 20:441-5.
https://www.ncbi.nlm.nih.gov/pubmed/28298828

Aim: Determination of the treatment outcome of mucoderm® as an alternative to the autologous connective tissue graft for peri-implant soft tissue augmentation as part of implant site development.

Study design:

Prospective, randomized, controlled clinical trial



- Implant placement
- Split thickness flap (mucoderm®)/full thickness flap (no graft)
- Repositioning of mucosal flap to cover the matrix/implant
- Measurement of soft tissue thickness with a customized metal stent at 2 sites
- Time points T0 and 6 months postoperatively
- Biopsy at 6 months

Results: mucoderm® led to a significant soft tissue increase at peri-implant sites with minimal pain and swelling for the patient when compared to no graft

Results:



- 1 mm below gingival margin increase of 117%
- 3 mm below gingival margin increase of 81%

Conclusion: mucoderm® is a suitable alternative to the patients own connective tissue in terms of soft tissue augmentation around dental implants with a mean soft tissue increase of +1.06 mm and good integration/remodeling evidenced by histological analyses.

botiss biomaterials GmbH
Hauptstr. 28 / 15806 Zossen / Germany
Tel.: + 49 33769 / 88 41 985
Fax: + 49 33769 / 88 41 986
contact@botiss.com
www.botiss-dental.com

Science Flash
clinical study

bone & tissue regeneration

botiss biomaterials

mucoderm® an efficient alternative for peri-implant soft tissue augmentation Part II

Scientific source:
Zafiropoulos GG, John G. Use of a Collagen Matrix for Augmentation of the Peri-implant Soft Tissue at the Time of Immediate Implant Placement. J Contemp Dent Pract 2017;18(5):1-6.
https://www.ncbi.nlm.nih.gov/pubmed/28512278

Aim: Determination of the treatment outcome of mucoderm® for peri-implant soft tissue augmentation in conjunction with immediate implant placement as an alternative to the patient's own connective tissue.

Study design:

Prospective, randomized, clinical trial

Technique 1: envelope flap and mucoderm® coronally, covered

Technique 2: coronally repositioned flap and mucoderm® covered by mucosa

27 implants in 27 patients

- Tooth extraction and implant placement
- Split thickness flap preparation
- Soft tissue augmentation with mucoderm® positioned on periosteum
- One of the two flap designs
- Measurement of soft tissue thickness with a customized metal stent at 1 side
- Time points T0 and 6 months postoperatively
- CBCT scans after 6 months

Results:

Results: mucoderm® led to a significant soft tissue increase at 6 months of immediate implant placement without any signs of complications.



- 1 mm below gingival margin soft tissue increase of 0.7 mm

Conclusion: mucoderm® is a valid alternative to the patients own connective tissue graft, which served to thicken the soft tissue in conjunction with immediate implant placement regardless of the flap design.

botiss biomaterials GmbH
Hauptstr. 28 / 15806 Zossen / Germany
Tel.: + 49 33769 / 88 41 985
Fax: + 49 33769 / 88 41 986
contact@botiss.com
www.botiss-dental.com